Korean Post-marketing Surveillance for Sprycel.
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 25 Apr 2016 Status changed from recruiting to completed.
- 08 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 May 2016, according to ClinicalTrials.gov record.
- 08 Mar 2016 Planned primary completion date changed from 1 Dec 2016 to 1 May 2016, according to ClinicalTrials.gov record.